CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to understand non-genetic mechanisms of drug resistance in cancer by identifying drug-tolerant cell populations. It utilizes advanced technologies to analyze epigenomic changes and seeks to find biomarkers for resistance in melanoma patients.
Resistance to anticancer drugs, which often develops from a heterogeneous pool of drug-tolerant cells known as minimal residual disease (MRD), is thought to mainly occur through acquisition of genetic alterations.
Emerging evidence indicates that drug resistance may also be acquired in absence of a genetic cause.
It remains unclear, however, whether genetic versus non-genetic mechanisms of resistance are selected in a stochastic manner, and what are the epigenomics mechanisms underlying the tran…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
